⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 1, 2024

Attenuating Renal Interstitial Fibrosis by Shenqi Pill via Reducing Inflammation Response Regulated by NF-κB Pathway In Vitro and In Vivo.

Hongshu Chen Yuanxiao Yang Xiaojie Zhou Yaorong Feng

View Full Paper

Ask AI

Bookmark

Share

Abstract

One of the most significant clinical features of chronic kidney disease is renal interstitial fibrosis (RIF). This study aimed to investigate the role and mechanism of Shenqi Pill (SQP) on RIF.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2024) studied this question.

synapsesocial.com/papers/68e76b0ab6db6435876e0fad https://doi.org/10.5254/kv5ap920

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Shenqi Pill Mitigates Renal Interstitial Fibrosis Through Weakening Notch1/Jag1 Pathway.2024
2Inhibitory Potential of Shen-Shuai-Ling Formulation on Renal Interstitial Fibrosis via Upregulation of PLZFpreclinical · 2022 · 4 citations
3Sanqi oral solution ameliorates renal fibrosis by suppressing fibroblast activation via HIF-1α/PKM2/glycolysis pathway in chronic kidney disease2024 · 18 citations
4Antifibrotic Effects of Yi‐Qi‐Jian‐Pi‐Xiao‐Yu Formula in Kidney via HIF1A‐Driven M1 Macrophage PolarizationOriginal Research · 2026
5Gut microbiota and metabolomic alterations underlying the therapeutic effects of SQJZ capsules in a rat model of chronic renal failureOriginal Research · 2026